Edodekin alfa
Edodekin alfa is a protein pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
471 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 49 | 13 | 1 | 1 | — | 53 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 22 | 3 | — | 1 | 3 | 26 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | 7 | 5 | 3 | 3 | 17 |
| Crohn disease | D003424 | EFO_0000384 | K50 | 2 | 6 | 2 | 3 | 4 | 16 |
| Inflammation | D007249 | MP_0001845 | — | 1 | 3 | 2 | 1 | 9 | 15 |
| Colorectal neoplasms | D015179 | — | — | 11 | 5 | — | 1 | — | 14 |
| Hepatitis c | D006526 | — | B19.2 | 3 | 1 | — | 3 | 1 | 7 |
| Ulcerative colitis | D003093 | EFO_0000729 | K51 | — | 1 | — | 1 | 4 | 6 |
| Healthy volunteers/patients | — | — | — | 2 | 1 | 1 | 1 | — | 4 |
| Sepsis | D018805 | EFO_0001420 | A41.9 | — | 2 | 1 | 1 | 1 | 4 |
Show 23 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 25 | 37 | 2 | — | 3 | 55 |
| Leukemia | D007938 | — | C95 | 7 | 8 | 2 | — | 1 | 16 |
| Covid-19 | D000086382 | — | U07.1 | — | 2 | 8 | — | 5 | 14 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 5 | 7 | 3 | — | 1 | 14 |
| Myeloid leukemia | D007951 | — | C92 | 5 | 6 | 1 | — | 1 | 11 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 7 | 5 | 1 | — | — | 11 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 5 | 6 | 1 | — | — | 10 |
| Myelodysplastic syndromes | D009190 | — | D46 | 5 | 4 | 1 | — | — | 8 |
| Fallopian tube neoplasms | D005185 | — | — | 6 | 3 | 1 | — | — | 8 |
| Ovarian epithelial carcinoma | D000077216 | — | — | 6 | 2 | 1 | — | — | 8 |
Show 55 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 16 | 6 | — | — | 1 | 20 |
| Recurrence | D012008 | — | — | 13 | 6 | — | — | — | 17 |
| Carcinoma | D002277 | — | C80.0 | 11 | 10 | — | — | — | 17 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | 9 | 6 | — | — | — | 14 |
| Lung neoplasms | D008175 | — | C34.90 | 13 | 6 | — | — | — | 14 |
| Non-small-cell lung carcinoma | D002289 | — | — | 12 | 6 | — | — | — | 13 |
| Lymphoma | D008223 | — | C85.9 | 7 | 7 | — | — | — | 12 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | 8 | 5 | — | — | — | 11 |
| Sarcoma | D012509 | — | — | 7 | 4 | — | — | 1 | 11 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 11 | 4 | — | — | — | 11 |
Show 152 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Immunologic deficiency syndromes | D007153 | — | D84.9 | 2 | — | — | — | 3 | 5 |
| Endometrial neoplasms | D016889 | EFO_0004230 | — | 3 | — | — | — | — | 3 |
| Adenocarcinoma | D000230 | — | — | 2 | — | — | — | — | 2 |
| Germ cell and embryonal neoplasms | D009373 | — | — | 2 | — | — | — | — | 2 |
| Mycobacterium infections | D009164 | — | A31.9 | 2 | — | — | — | — | 2 |
| Glandular and epithelial neoplasms | D009375 | — | — | 2 | — | — | — | — | 2 |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
| Adenosquamous carcinoma | D018196 | — | — | 1 | — | — | — | — | 1 |
| Salivary gland neoplasms | D012468 | EFO_0003826 | D11 | 1 | — | — | — | — | 1 |
| Nasopharyngeal carcinoma | D000077274 | — | — | 1 | — | — | — | — | 1 |
Show 53 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 2 | 2 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | — | — | — | 2 | 2 |
| Burns | D002056 | — | T30.0 | — | — | — | — | 2 | 2 |
| Chronic renal insufficiency | D051436 | — | N18 | — | — | — | — | 2 | 2 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | — | — | 2 | 2 |
| Periodontitis | D010518 | EFO_0000649 | K05.3 | — | — | — | — | 2 | 2 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 2 | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 1 | 1 |
| Dermatitis | D003872 | — | L30.9 | — | — | — | — | 1 | 1 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | — | — | 1 | 1 |
Show 55 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Edodekin alfa |
| INN | edodekin alfa |
| Description | Edodekin alfa is a protein pharmaceutical. It is currently being investigated in clinical studies. |
| Classification | Protein |
| Drug class | interleukins: interleukin-12 analogues and derivatives |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL2109059 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | — |
| UNII ID | 31Z82G8ME1 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
14 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use